Effectiveness of biosimilar drugs in the treatment of renal anemia: A case series
Introduction Patients with chronic kidney disease usually have anemia secondary to an erythropoietin deficit. The emergence of biosimilar drugs of erythropoiesis-stimulating agents ensures broader access to these treatments. Objective This study analyzes the effectiveness of an epoetin α biosim...
Guardado en:
Autores principales: | Patricia Muñoz Ramos, Yohana Gil Giraldo, Vicente Álvarez Chiva |
---|---|
Formato: | article |
Lenguaje: | EN ES |
Publicado: |
Medwave Estudios Limitada
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a2ce73468f3043b2a5060f8e35081468 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Biosimilars: presumption of guilt
por: Marina Vladimirovna Shestakova, et al.
Publicado: (2011) -
Anemia associated with chronic heart failure: current concepts
por: Shah R, et al.
Publicado: (2013) -
EFFECT OF SUBCUTANEOUS RECOMBINANT HUMAN ERYTHROPOIETIN ON BLOOD PRESSURE IN PRE-DIALYSIS CHRONIC KIDNEY DISEASE (CKD) PATIENTS
por: Muhammad Sajid Hussain, et al.
Publicado: (2021) -
Pharmacoutilization of epoetins in naïve patients with hematological malignancies in an unselected Italian population under clinical practice setting: a comparative analysis between originator and biosimiliars
por: Perrone V, et al.
Publicado: (2016) -
Physiology and Inflammation Driven Pathophysiology of Iron Homeostasis—Mechanistic Insights into Anemia of Inflammation and Its Treatment
por: Lukas Lanser, et al.
Publicado: (2021)